Presentations for MSToronto2026

Oral Presentations

Dzau et al: Emulation of a Target Placebo-Controlled Trial in Multiple Sclerosis Registry Data

Roos et al: Exit Strategies after Anti-Cell Trafficking Therapies in Multiple Sclerosis Patients Aged ≥50 Years: a Target Trial Emulation

Posters

Lizak et al: Is siponimod unique in the treatment of secondary progressive MS?  |  Affiliations & Disclosure Statements  |  Supplementary Information  | 

Roos et al: Progression independent of relapse activity in a population with relapse-onset multiple sclerosis

Sharmin et al: Optimal responders to autologous hematopoietic stem cell transplant versus natalizumab in relapsing-remitting multiple sclerosis

Haile et al: A causal effect of early high-efficacy therapy across ages

Iqbal et al: Individualized treatment response in multiple sclerosis predicted with machine learning